BF Biosciences Limited BFBIO
Rs 129.03
Vol159,179Updated10:3029 Jul 2026
01—At a Glance
The headline take on BFBIO — valuation, income, returns, and efficiency
Consolidated snapshot
02—Price & Performance
Closing prices across timeframes, returns, and range context
BFBIO — Price History
Daily closing series · toggle period below
03—Key Metrics
Valuation, profitability, structure, and risk in one grid
04—Dividend History & Yield
Payout track record, yield trend, and upcoming distribution
Latest Payout
Dividend Per Share Trend
05—Financials & Earnings
Income, balance sheet, and key ratios from published accounts
BFBIO's market capitalisation stands at Rs 11.40B as of 29 Jul 2026 — down 21.6% over the past 12 months (from Rs 14.53B).
Financial Statements
How OGDC's income and balance sheet have evolved
| PKR Millions | FY25 | FY24 | FY23 | Trend |
|---|---|---|---|---|
| Net Sales / Revenue | 5,837 | 3,659 | 1,810 | |
| Cost of Sales | 3,550 | 2,126 | 1,360 | |
| Gross Profit | 2,288 | 1,533 | 450 | |
| Administrative Expenses | 61 | 40 | 23 | |
| Operating Profit | 782 | 775 | 290 | |
| EBITDA | 991 | 812 | 325 | |
| Other Income | 140 | 22 | 94 | |
| Financial Charges | 128 | 151 | 153 | |
| Profit Before Tax | 724 | 582 | 203 | |
| Taxation | 277 | 196 | 53 | |
| Profit After Tax | 447 | 386 | 150 | |
| EPS - Basic (Rs) | Rs 5.52 | Rs 6.09 | Rs 2.35 |
All figures in PKR millions from published accounts.
Profitability & Returns
Margins, returns on capital, and earnings per share
Latest · FY25
| Ratio | Value |
|---|---|
| Net profit margin | 7.7% |
| Gross profit margin | 39.2% |
| EBITDA margin | 17.0% |
| EBIT margin | 13.4% |
Net profit margin
Net profit ÷ revenue · %
Financial Health
Coverage, leverage, and the strength of the balance sheet
Latest · FY25
| Ratio | Value |
|---|---|
| Effective tax rate | 38.3% |
Effective tax rate
Taxation ÷ profit before tax · %
Market cap trajectory
Close × current shares outstanding · current Rs 11.40B
Valuation & Capital Returns
What the market is paying for BFBIO, and what it returns to shareholders
Latest · FY25
| Ratio | Value |
|---|---|
| Price to earnings | 25.46x |
| Price to sales | 2.13x |
Price to earnings
Period-end price ÷ EPS · times
06—Technical Analysis
Trading signal, moving averages, momentum, and key levels
10-day SMA (Rs 130.00) is below the 30-day SMA (Rs 137.77). RSI at 38 sits in the neutral band.
Moving AverageThe average close over a set window (10/30/200 days) — smooths daily noise to reveal the trend.Read the full guide →
| Period | Value | vs Current | Position |
|---|---|---|---|
| SMA 10 | Rs 130.00 | +0.75% | Below |
| SMA 30 | Rs 137.77 | +6.78% | Below |
| SMA 60 | Rs 137.58 | +6.62% | Below |
| SMA 200 | Rs 147.06 | +13.98% | Below |
At 38, momentum sits within the neutral band (30–70), suggesting balanced buying and selling pressure.
- MACD-3.18
- Signal-2.79
- Histogram-0.39
07—Leverage Insights
MTS, margin financing, futures open interest, and combined exposure
Leverage Composition
MTS · MFS stacked over the selected window
No blank sales
No net blank (short) sales reported for BFBIO on the latest PSX DFC report.
08—Settlement Insights
UIN-wise settlement concentration and price context
Metrics and charts over the selected trailing window
Settlement % Trajectory
Solid = UIN settlement % · Dashed = 14-session EMA
As of 16 Jul 2026
Price vs Settlement
Close price (left axis) · UIN settlement % (right axis)
10—About the Company
Business description, governance, and corporate information
BF Biosciences Limited ("BFBL", "Company", or the "Issuer") was incorporated as an unlisted public limited company under the Companies Ordinance, 1984 (now Companies Act, 2017) in 2006, and operates within the pharmaceutical industry. BFBL is a 80%:20% joint venture between Ferozsons Laboratories Limited and the Bagó Group of Argentina. The Company's core operations involve the import, manufacturing, marketing and distribution of pharmaceutical products.
Corporate Information
- RegistrarCDC Share Registrar Services Limited, CDC House, 99-B, Block-B, S.M.C.H.S, Main Shahrah Faisal, Karachi
- AuditorKPMG Taseer Hadi & Co. Chartered Accountants
- Websitewww.bfbio.com
- Address197-A, The Mall, Rawalpindi, Pakistan
- SectorPharmaceuticals
- Financial Year EndJune
Key People
| Name | Role |
|---|---|
MFMuhammad Farhan Rafiq | CEO |
SMSebastian Martin Ferrarassi | Chairperson |
ARAbdur Rehman | Company Secretary |
Reports & Filings
- Quarterly Report — 31 Mar 2026PDF
- Quarterly Report — 31 Dec 2025PDF
- Quarterly Report — 30 Sept 2025PDF
- Quarterly Report — 31 Mar 2025PDF
- Annual Report FY2025PDF
- Quarterly Report — 31 Dec 2024PDF
- Quarterly Report — 30 Sept 2024PDF
- Annual Report FY2024PDF
Sourced from official PSX financial-report submissions.
11—Recent Announcements
Latest company filings as reported on PSX
Filings and disclosures from the PSX announcement feed
- 14 Jul 2026OtherApproval of Annual Budget for FY 2026-27
- 06 Jul 2026Financial ResultsBoard Meeting Other Than Financial Results
- 09 Jun 2026Others
- 02 Jun 2026Others
- 01 Jun 2026Others
- 30 Apr 2026Financial Results
- 28 Apr 2026Financial Results
- 20 Apr 2026Board MeetingsBoard Meeting
12—Peers in Pharmaceuticals
How the cohort is moving — same-sector stocks by market cap
BFBIO vs Pharmaceuticals sector median
| Metric | BFBIO | Sector median |
|---|---|---|
| P/E RatioShare price ÷ earnings per share — the price you pay for each rupee of annual profit. Compare within a sector.Read the full guide → | 23.4x | 16.0x |
| Dividend YieldTrailing-12-month cash dividends ÷ share price. A high yield can signal income — or a falling price.Read the full guide → | 0.0% | 4.0% |
| Return on EquityNet profit ÷ shareholders' equity — how hard the company works each rupee investors have put in.Read the full guide → | 12.7% | 22.3% |
| 1-Year Return | -21.5% | -8.7% |
| Market CapitalisationShare price × total shares — the company's full market value, and the basis for index weightings.Read the full guide → | Rs 11.40B | Rs 27.79B |
Pharmaceuticals · sector heat
13—Frequently Asked Questions
The most common questions investors ask about BFBIO
Frequently Asked Questions
BFBIO closed at Rs 129.03 on 29 Jul 2026, down 0.32% on the day, within a 52-week range of Rs 124.00–189.97. Prices on this page refresh through the trading day; log in to BSL for live quotes.
BF Biosciences Limited ("BFBL", "Company", or the "Issuer") was incorporated as an unlisted public limited company under the Companies Ordinance, 1984 (now Companies Act, 2017) in 2006, and operates within the pharmaceutical industry. See About the Company on this page for the full profile, management, and corporate information.
BFBIO has not declared a cash dividend in the recent PSX record — some companies reinvest earnings instead; see the Financials section. For income ideas, browse the highest dividend yield stocks on PSX.
Yes — BF Biosciences Limited is on the PSX's Shariah-compliant (KMI All Shares) list. Browse all Shariah-compliant PSX stocks.
BFBIO trades at 23.4x earnings against a Pharmaceuticals median of 16.0x. The full comparison table and peer list are in the Peers section, or explore the Pharmaceuticals sector page.
Annual reports from FY2024 to FY2025 are linked under Reports & Filings in the About section of this page, sourced from official PSX submissions.
Open a BSL trading account, fund it, and place your BFBIO order on the Pakistan Stock Exchange — account opening takes minutes online, with PSX execution, research, and concierge support included.
Quotes and metrics refresh on a regular cadence through the trading day and after the close. For streaming real-time PSX prices and order placement, log in to your BSL account.
Ready to invest in BFBIO?
Open a BSL trading account in under 10 minutes
Buy and sell BFBIO and 550+ other PSX-listed stocks with low commissions, real-time data, and a concierge research desk backing every trade.